Serdar Sander

ORCID: 0000-0003-1667-6198
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Urological Disorders and Treatments
  • Urinary and Genital Oncology Studies
  • Urinary Bladder and Prostate Research
  • Bladder and Urothelial Cancer Treatments
  • Pelvic floor disorders treatments
  • Urologic and reproductive health conditions
  • Pediatric Urology and Nephrology Studies
  • Prostate Cancer Treatment and Research
  • Congenital Anomalies and Fetal Surgery
  • Testicular diseases and treatments
  • Prostate Cancer Diagnosis and Treatment
  • Hernia repair and management
  • Hormonal and reproductive studies
  • Kidney Stones and Urolithiasis Treatments
  • Esophageal and GI Pathology
  • Gastrointestinal disorders and treatments
  • Urinary Tract Infections Management
  • Intestinal Malrotation and Obstruction Disorders
  • Estrogen and related hormone effects
  • Vascular anomalies and interventions
  • Renal and related cancers
  • Medical Education and Admissions
  • Sexual Differentiation and Disorders
  • Parasitic infections in humans and animals
  • Ureteral procedures and complications

Ankara University
2022

Pediatrics and Genetics
2022

İstanbul Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi
2014-2018

Sağlık Bilimleri Üniversitesi
2018

Laboratoire de Chimie Moléculaire et Thioorganique
2018

Software (Spain)
2018

Ministry of Health
2010-2015

Erciyes University
2010

Bakırköy Psychiatric Hospital
1998-2008

Istanbul University
1994-2006

A randomized open comparative cross-over trial was carried out in 20 postmenopausal women, mean age 69 years, suffering from urinary incontinence due to urethral sphincteric insufficiency. They were treated with phenylpropanolamine (PPA) 50 mg p.o. twice daily or estriol vaginal suppositories 1 separately and combination for periods of 4 weeks. Urodynamic investigations before after each period treatment. Both PPA increased the maximal closure pressure continence area significantly compared...

10.1159/000280978 article EN Urologia Internationalis 1984-01-01

An analysis by the Nordic Cooperative Bladder Cancer Study Group concerned possible benefit of neoadjuvant chemotherapy--given before scheduled low-dose irradiation and cystectomy. In trial, started in 1985, 311 patients with locally advanced bladder cancer, T1 grade 3, T2-T4a NXMO, were randomly allocated to a 'chemotherapy' or 'no chemotherapy' group. Chemotherapy consisted two cycles comprising cisplatin 70 mg/m2 doxorubicin 30 mg/m2, 3-week interval between 1 2. All irradiated 4 Gy daily...

10.3109/00365599309180447 article EN Scandinavian Journal of Urology and Nephrology 1993-09-01

Previous studies have shown that activated T cells can successfully cross endothelial barriers and will accumulate in tissue which contains their specific antigen. Myelin (e.g. myelin basic protein specific) are recognized to play an important role the induction of experimental autoimmune demyelinating disease CNS been induce blood-brain barrier breakdown effectively. In this study we injected reactive a non-neural antigen (ovalbumin) systemically into Lewis rats caused them thoracic dorsal...

10.1093/brain/122.7.1283 article EN Brain 1999-07-01

The human testis and epididymis contain two distinct androgen binding components, one with physicochemical properties identical to the receptor found in other target tissues another, protein (ABP), which shares same characteristics as testosterone globulin (TeBG). Simultaneous assays of ABP corticosteroid (CBG, an exclusive blood protein) testicular extracts suggest that second component could be readily explained by contamination TeBG rather than existence a specific ABP. levels...

10.1111/j.1365-2605.1978.tb00624.x article EN Andrology 1978-12-01

Aim: To standardize diagnosis and treatment of childhood Wilms tumor (WT) in Turkey. Methods patients: Between 1998 2006, WT patients were registered from 19 centers. Patients <16 years with unilateral whose started first postoperative 3 weeks included. Treatments stage I favorable (FH) unfavorable histology (UH) patients, VCR + Act-D; IIA FH, IIB Act-D radiotherapy (RT); III–IV adriamycin (ADR) RT; stages II–IV UH tumors, ADR etoposide RT. Results: 165/254 cases eligible (bilateral, 5.9%)...

10.3109/08880010903447375 article EN Pediatric Hematology and Oncology 2010-04-05
Coming Soon ...